Literature DB >> 21455215

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

O Abdel-Wahab, A Pardanani, J Patel, M Wadleigh, T Lasho, A Heguy, M Beran, D G Gilliland, R L Levine, A Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21455215      PMCID： PMC4641450          DOI： 10.1038/leu.2011.58

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2010-10-14       Impact factor: 22.113

2.  Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.

Authors:  Hadrian Szpurka; Anna M Jankowska; Hideki Makishima; Juraj Bodo; Nelli Bejanyan; Eric D Hsi; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Leuk Res       Date:  2010-03-23       Impact factor: 3.156

3.  Mutations of ASXL1 gene in myeloproliferative neoplasms.

Authors:  N Carbuccia; A Murati; V Trouplin; M Brecqueville; J Adélaïde; J Rey; W Vainchenker; O A Bernard; M Chaffanet; N Vey; D Birnbaum; M J Mozziconacci
Journal:  Leukemia       Date:  2009-07-16       Impact factor: 11.528

4.  Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias.

Authors:  N Carbuccia; V Trouplin; V Gelsi-Boyer; A Murati; J Rocquain; J Adélaïde; S Olschwang; L Xerri; N Vey; M Chaffanet; D Birnbaum; M J Mozziconacci
Journal:  Leukemia       Date:  2009-10-29       Impact factor: 11.528

5.  ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; Julien Roquain; José Adélaïde; Nadine Carbuccia; Benjamin Esterni; Pascal Finetti; Anne Murati; Christine Arnoulet; Hacène Zerazhi; Hacène Fezoui; Zoulika Tadrist; Meyer Nezri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2010-09-29       Impact factor: 6.998

6.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.

Authors:  Thomas Ernst; Andrew J Chase; Joannah Score; Claire E Hidalgo-Curtis; Catherine Bryant; Amy V Jones; Katherine Waghorn; Katerina Zoi; Fiona M Ross; Andreas Reiter; Andreas Hochhaus; Hans G Drexler; Andrew Duncombe; Francisco Cervantes; David Oscier; Jacqueline Boultwood; Francis H Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

7.  Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.

Authors:  Benoîte Pérez; Olivier Kosmider; Bruno Cassinat; Aline Renneville; Julie Lachenaud; Sophie Kaltenbach; Yves Bertrand; André Baruchel; Christine Chomienne; Michaela Fontenay; Claude Preudhomme; Hélène Cavé
Journal:  Br J Haematol       Date:  2010-10-19       Impact factor: 6.998

8.  High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.

Authors:  J Boultwood; J Perry; R Zaman; C Fernandez-Santamaria; T Littlewood; R Kusec; A Pellagatti; L Wang; R E Clark; J S Wainscoat
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528
  8 in total
  90 in total

Review 1.  Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.

Authors:  Shuhei Asada; Toshio Kitamura
Journal:  Int J Hematol       Date:  2018-12-05       Impact factor: 2.490

2.  DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.

Authors:  O Abdel-Wahab; A Pardanani; R Rampal; T L Lasho; R L Levine; A Tefferi
Journal:  Leukemia       Date:  2011-04-26       Impact factor: 11.528

Review 3.  Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Authors:  Su-Jiang Zhang; Omar Abdel-Wahab
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

4.  Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.

Authors:  Gary W Reuther
Journal:  Am J Cancer Res       Date:  2011-05-29       Impact factor: 6.166

Review 5.  Clonal hematopoiesis.

Authors:  Max Jan; Benjamin L Ebert; Siddhartha Jaiswal
Journal:  Semin Hematol       Date:  2016-10-20       Impact factor: 3.851

6.  Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.

Authors:  Mandy Brecqueville; Jérôme Rey; Raynier Devillier; Arnaud Guille; Rémi Gillet; José Adélaide; Véronique Gelsi-Boyer; Christine Arnoulet; Max Chaffanet; Marie-Joelle Mozziconacci; Norbert Vey; Daniel Birnbaum; Anne Murati
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

Review 7.  Perspectives and future directions for epigenetics in hematology.

Authors:  Margaret A Goodell; Lucy A Godley
Journal:  Blood       Date:  2013-05-21       Impact factor: 22.113

Review 8.  Epigenetic alterations in hematopoietic malignancies.

Authors:  Young Rock Chung; Emma Schatoff; Omar Abdel-Wahab
Journal:  Int J Hematol       Date:  2012-09-27       Impact factor: 2.490

9.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Authors:  Daichi Inoue; Jiro Kitaura; Katsuhiro Togami; Koutarou Nishimura; Yutaka Enomoto; Tomoyuki Uchida; Yuki Kagiyama; Kimihito Cojin Kawabata; Fumio Nakahara; Kumi Izawa; Toshihiko Oki; Akie Maehara; Masamichi Isobe; Akiho Tsuchiya; Yuka Harada; Hironori Harada; Takahiro Ochiya; Hiroyuki Aburatani; Hiroshi Kimura; Felicitas Thol; Michael Heuser; Ross L Levine; Omar Abdel-Wahab; Toshio Kitamura
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 10.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.